PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC lowered its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) by 37.3% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,870,217 shares of the biopharmaceutical company’s stock after selling 1,111,342 shares during the period. Janus Henderson Group PLC owned approximately 2.43% of PTC Therapeutics worth $69,391,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Assenagon Asset Management S.A. lifted its position in shares of PTC Therapeutics by 21.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 372,827 shares of the biopharmaceutical company’s stock worth $11,401,000 after purchasing an additional 66,596 shares during the last quarter. Intech Investment Management LLC purchased a new stake in shares of PTC Therapeutics in the third quarter valued at about $698,000. Bank of New York Mellon Corp boosted its holdings in shares of PTC Therapeutics by 17.1% in the second quarter. Bank of New York Mellon Corp now owns 279,049 shares of the biopharmaceutical company’s stock valued at $8,533,000 after acquiring an additional 40,840 shares in the last quarter. Quest Partners LLC boosted its holdings in PTC Therapeutics by 433.9% during the third quarter. Quest Partners LLC now owns 22,359 shares of the biopharmaceutical company’s stock worth $830,000 after buying an additional 18,171 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in PTC Therapeutics by 7.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 706,730 shares of the biopharmaceutical company’s stock worth $26,220,000 after buying an additional 47,902 shares in the last quarter.

Insiders Place Their Bets

In related news, Director Jerome B. Zeldis sold 24,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $51.50, for a total value of $1,236,000.00. Following the completion of the sale, the director now directly owns 14,500 shares in the company, valued at approximately $746,750. The trade was a 62.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Mark Elliott Boulding sold 85,600 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $52.26, for a total value of $4,473,456.00. Following the sale, the vice president now owns 92,389 shares of the company’s stock, valued at $4,828,249.14. The trade was a 48.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 196,950 shares of company stock valued at $10,251,735 over the last 90 days. 5.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have issued reports on PTCT shares. StockNews.com raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday. Raymond James began coverage on shares of PTC Therapeutics in a research report on Thursday, October 10th. They set a “market perform” rating for the company. UBS Group upped their price target on shares of PTC Therapeutics from $47.00 to $71.00 and gave the stock a “buy” rating in a research report on Tuesday. Barclays increased their price objective on shares of PTC Therapeutics from $45.00 to $56.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Finally, Baird R W raised shares of PTC Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 4th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $52.38.

PTC Therapeutics Trading Down 2.9 %

PTCT stock opened at $48.40 on Friday. The business’s 50-day moving average price is $41.28 and its two-hundred day moving average price is $36.74. The firm has a market cap of $3.73 billion, a PE ratio of -8.15 and a beta of 0.63. PTC Therapeutics, Inc. has a 1-year low of $23.58 and a 1-year high of $54.16.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.